This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

This study has been terminated.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Identifier:
First received: May 24, 2004
Last updated: April 25, 2011
Last verified: April 2011
The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Condition Intervention Phase
Anemia Drug: epoetin alfa Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Study Start Date: February 2004
Study Completion Date: October 2004

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body weight >/=99 lbs
  • ECOG 0-2
  • Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
  • Screening hemoglobin level of </=11.0 g/dL for men or </=10.0 for women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00083486

United States, Arkansas
Heritage Physician Group-Oncology
Hot Springs, Arkansas, United States, 71913
United States, Georgia
Spalding Oncology Services
Griffin, Georgia, United States, 30224
United States, Illinois
Southern Illinois Hematology
Centralia, Illinois, United States, 62801
United States, Maryland
BioLab Research
Rockville, Maryland, United States, 20852
United States, New York
Slocum-Dickson Medical Group, PC
New Hartford, New York, United States, 13413
United States, North Carolina
NorthEast Urology Research
Concord, North Carolina, United States
United States, Ohio
Mid Ohio Oncology Hematology
Columbus, Ohio, United States, 43213
United States, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States, 19102
United States, South Carolina
Caroline Cancer Center
Aiken, South Carolina, United States, 29403
Charleston Hematology Oncology
Charleston, South Carolina, United States, 29403
Charleston Cancer Care
Charleston, South Carolina, United States, 29406
United States, Tennessee
Volunteer Research Group
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information Identifier: NCT00083486     History of Changes
Other Study ID Numbers: CR010939
Study First Received: May 24, 2004
Last Updated: April 25, 2011

Additional relevant MeSH terms:
Hematologic Diseases
Epoetin Alfa
Hematinics processed this record on September 21, 2017